Quote:
|
Originally Posted by atomicone Max I have a question for you. I recently went of rHGH for 6 weeks after being on it for 1.8 years straight from doses between 2-5iu ED. I just stared back up at 5iu ED since I've gained about 5lbs of stomach fat back. I'm a little concerned that running it the way I have been will shut down my natural production permantly, as I'm only 33 years old. What light can you shed on this? |
Atomic,
Very good question. There's no doubt but what exogenous
HGH, even at low doses, suppresses endogenous
HGH. (see the following, recent study) However, does long term exogenous
HGH permanently suppress your natural
GH production... I really don't know.
MaxRep
__________________________________________________ ____________
1: J Clin Endocrinol Metab. 2004 Aug;89(8):3956-64.
Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (
GH) release following short-term low-dose
GH administration in young healthy adults.
Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D.
Department of Paediatrics, University of Cambridge, Cambridge CB2 2QQ, United Kingdom.
High-dose
GH administration is commonly associated with impaired insulin sensitivity (S(I)) in humans. Paradoxically we have shown that low-dose
GH (1.7 microg/kg.d) administration enhances beta-cell function in young healthy adults.
In the present double-blind, placebo-controlled, cross-over study, we explored the physiological effects of this low
GH dose on glucose metabolism in 12 young healthy adults (seven males, 19-29 yr).
At pretreatment and after each 14-d treatment block, overnight metabolic profiles were assessed followed by a hyperinsulinemic euglycemic clamp, whereas fasting blood samples were collected weekly.In subjects treated with
GH first (group A, n = 6),
GH treatment increased total
IGF-I (P < 0.05) and
IGF binding protein-3 (P < 0.01) after 7 d, but these levels subsequently returned to pretreatment levels after 14 d. In contrast, free
IGF-I increased (P < 0.05), and overnight
GH pulse peak amplitude decreased (P < 0.01) after 14 d. In subjects treated with placebo first (group B, n = 6), all biochemical parameters were unchanged after placebo treatment, whereas the changes in free and total IGF-I were similar to those of group A after
GH treatment. Combined clamp data from both groups A and B (n = 12) showed that 14-d
GH treatment decreased overnight plasma insulin levels (P < 0.02) and hepatic glucose appearance (P < 0.05) and increased S(I) (P < 0.01). Of note, the
GH-induced changes in S(I) positively correlated with the changes in free IGF-I (r = 0.72, P < 0.01).
In conclusion, low-dose GH administration enhanced S(I) and suppressed endogenous peak GH release, and we hypothesize that these effects are the direct result of increased serum levels of free IGF-I.
Publication Types:
· Clinical Trial
· Randomized Controlled Trial
PMID: 15292333 [PubMed - indexed for MEDLINE]
Linear Mode
